The company is facing a combination of slow revenue growth, unresolved legal battles over talc products, and looming drug ...

Former Texas guard Tre Johnson is reportedly performing well in workouts and improving his stock ahead of the draft on ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $100.92, with a ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Fintel reports that on June 20, 2025, Oppenheimer downgraded their outlook for Johnson Controls International (NYSE:JCI) from ...

Boost your dividend portfolio with Allianz & LVMH. Read more on high yields, growth potential, and diversification for ...

Trading near 52-week highs of over $200 a share, Jabil (JBL) stock may be poised for more upside after posting strong results for its fiscal third quarter this week.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated ...

The city is losing its transportation commissioner right before stock cars race around downtown. Department of Transportation ...

As self-driving technology improves, and robo-taxis proliferate across America, investors will have to think about consumer’s ...

Johnson Controls shares have outperformed peer averages both quarter-to-date and year-to-date, with valuation now sitting at historical highs. According to Oppenheimer, this valuation implies faster ...

NBA Draft is less than one week away, which means we will soon know exactly where each of the top prospects will begin their ...